BioPharmaSpec, a global Contract Research Organization (CRO), has announced three new European facilities.
 
The new facilities will focus on discovery and R&D services, offering structural and physicochemical characterization services for a wide variety of biopharmaceutical products. These include monoclonal antibodies, antibody-drug conjugates, cell and gene therapy products, bioactive peptides, oligonucleotides and carbohydrates, together with HCP identification and the quantitation of other relevant product- and process-related impurities.
 
“The Freiburg, Bergamo and Vilnius sites join our existing UK and US-based facilities to create the BioPharmaSpec Group of companies, serving the global biopharmaceutical industry,” said Prof. Howard R. Morris FRS, Founder of the BioPharmaSpec Group of companies.
 
“With the opening of these new laboratories in January 2025 and recruitment of local expert scientists, we are strategically and uniquely placed to provide our expanding global client base with the highest levels of technical and customer service,” said Director of Business Development, Lindsay McGowan.
 
Alongside modern office space and meeting rooms, the new laboratories will host some of BioPharmaSpec’s instrumentation including Waters Select Series CYCLIC Ion Mobility Separation (IMS) High Definition LC-MS/MS with ECD, SCIEX ZenoTOF 7600 LC-MS/MS with EAD, Waters Xevo TQ Absolute and Waters Xevo G3 LC-MS/MS Q-TOFs. This high-end instrumentation, supported by expert scientific advice, enables clients from across the globe to access high-quality structural characterization services with fast turnaround times.